vs

Side-by-side financial comparison of PRO DEX INC (PDEX) and AVITA Medical, Inc. (RCEL). Click either name above to swap in a different company.

PRO DEX INC is the larger business by last-quarter revenue ($18.7M vs $17.6M, roughly 1.1× AVITA Medical, Inc.). PRO DEX INC runs the higher net margin — 11.7% vs -66.0%, a 77.7% gap on every dollar of revenue. On growth, PRO DEX INC posted the faster year-over-year revenue change (11.1% vs -4.3%). PRO DEX INC produced more free cash flow last quarter ($3.5M vs $-6.1M). Over the past eight quarters, AVITA Medical, Inc.'s revenue compounded faster (26.0% CAGR vs 14.3%).

Pro Dex Inc is a precision manufacturing enterprise that produces custom machined components, subassemblies and finished products primarily for medical device original equipment manufacturers, as well as clients in the aerospace and industrial sectors, with its core operating market covering North America.

Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East...

PDEX vs RCEL — Head-to-Head

Bigger by revenue
PDEX
PDEX
1.1× larger
PDEX
$18.7M
$17.6M
RCEL
Growing faster (revenue YoY)
PDEX
PDEX
+15.4% gap
PDEX
11.1%
-4.3%
RCEL
Higher net margin
PDEX
PDEX
77.7% more per $
PDEX
11.7%
-66.0%
RCEL
More free cash flow
PDEX
PDEX
$9.6M more FCF
PDEX
$3.5M
$-6.1M
RCEL
Faster 2-yr revenue CAGR
RCEL
RCEL
Annualised
RCEL
26.0%
14.3%
PDEX

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
PDEX
PDEX
RCEL
RCEL
Revenue
$18.7M
$17.6M
Net Profit
$2.2M
$-11.6M
Gross Margin
30.8%
81.2%
Operating Margin
17.5%
-59.1%
Net Margin
11.7%
-66.0%
Revenue YoY
11.1%
-4.3%
Net Profit YoY
7.2%
-0.3%
EPS (diluted)
$0.66
$-0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PDEX
PDEX
RCEL
RCEL
Q4 25
$18.7M
$17.6M
Q3 25
$18.5M
$17.1M
Q2 25
$17.5M
$18.4M
Q1 25
$17.4M
$18.5M
Q4 24
$16.8M
$18.4M
Q3 24
$14.9M
$19.5M
Q2 24
$15.0M
$15.2M
Q1 24
$14.3M
$11.1M
Net Profit
PDEX
PDEX
RCEL
RCEL
Q4 25
$2.2M
$-11.6M
Q3 25
$4.7M
$-13.2M
Q2 25
$1.2M
$-9.9M
Q1 25
$3.3M
$-13.9M
Q4 24
$2.0M
$-11.6M
Q3 24
$2.5M
$-16.2M
Q2 24
$1.6M
$-15.4M
Q1 24
$655.0K
$-18.7M
Gross Margin
PDEX
PDEX
RCEL
RCEL
Q4 25
30.8%
81.2%
Q3 25
29.0%
81.3%
Q2 25
19.9%
81.2%
Q1 25
33.3%
84.7%
Q4 24
30.2%
87.6%
Q3 24
34.6%
83.7%
Q2 24
27.2%
86.1%
Q1 24
28.0%
86.4%
Operating Margin
PDEX
PDEX
RCEL
RCEL
Q4 25
17.5%
-59.1%
Q3 25
16.8%
-53.6%
Q2 25
7.7%
-60.5%
Q1 25
20.9%
-63.9%
Q4 24
16.0%
-54.1%
Q3 24
20.2%
-70.6%
Q2 24
15.6%
-102.8%
Q1 24
15.5%
-155.0%
Net Margin
PDEX
PDEX
RCEL
RCEL
Q4 25
11.7%
-66.0%
Q3 25
25.3%
-77.3%
Q2 25
6.8%
-53.9%
Q1 25
18.8%
-74.9%
Q4 24
12.1%
-63.0%
Q3 24
16.6%
-82.9%
Q2 24
10.6%
-101.3%
Q1 24
4.6%
-168.0%
EPS (diluted)
PDEX
PDEX
RCEL
RCEL
Q4 25
$0.66
$-0.37
Q3 25
$1.40
$-0.46
Q2 25
$0.33
$-0.38
Q1 25
$0.98
$-0.53
Q4 24
$0.61
$-0.44
Q3 24
$0.75
$-0.62
Q2 24
$0.44
$-0.60
Q1 24
$0.19
$-0.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PDEX
PDEX
RCEL
RCEL
Cash + ST InvestmentsLiquidity on hand
$6.1M
$18.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$41.6M
$-16.6M
Total Assets
$62.3M
$56.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PDEX
PDEX
RCEL
RCEL
Q4 25
$6.1M
$18.2M
Q3 25
$10.1M
$23.3M
Q2 25
$6.8M
$15.7M
Q1 25
$5.5M
$25.8M
Q4 24
$4.7M
$35.9M
Q3 24
$7.8M
$44.4M
Q2 24
$6.8M
$54.1M
Q1 24
$7.8M
$68.2M
Total Debt
PDEX
PDEX
RCEL
RCEL
Q4 25
Q3 25
Q2 25
$15.4M
Q1 25
Q4 24
Q3 24
Q2 24
$12.0M
Q1 24
Stockholders' Equity
PDEX
PDEX
RCEL
RCEL
Q4 25
$41.6M
$-16.6M
Q3 25
$41.5M
$-6.7M
Q2 25
$36.6M
$-12.9M
Q1 25
$35.3M
$-4.6M
Q4 24
$31.8M
$4.5M
Q3 24
$30.9M
$12.2M
Q2 24
$30.9M
$23.9M
Q1 24
$30.9M
$32.6M
Total Assets
PDEX
PDEX
RCEL
RCEL
Q4 25
$62.3M
$56.4M
Q3 25
$64.3M
$63.7M
Q2 25
$61.2M
$58.1M
Q1 25
$64.3M
$69.6M
Q4 24
$60.4M
$79.7M
Q3 24
$54.3M
$81.1M
Q2 24
$52.5M
$87.8M
Q1 24
$50.5M
$97.4M
Debt / Equity
PDEX
PDEX
RCEL
RCEL
Q4 25
Q3 25
Q2 25
0.42×
Q1 25
Q4 24
Q3 24
Q2 24
0.39×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PDEX
PDEX
RCEL
RCEL
Operating Cash FlowLast quarter
$3.6M
$-5.4M
Free Cash FlowOCF − Capex
$3.5M
$-6.1M
FCF MarginFCF / Revenue
18.8%
-34.7%
Capex IntensityCapex / Revenue
0.4%
3.8%
Cash ConversionOCF / Net Profit
1.63×
TTM Free Cash FlowTrailing 4 quarters
$-33.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PDEX
PDEX
RCEL
RCEL
Q4 25
$3.6M
$-5.4M
Q3 25
$2.3M
$-5.2M
Q2 25
$-173.0K
$-10.2M
Q1 25
$754.0K
$-10.3M
Q4 24
$-4.2M
$-8.1M
Q3 24
$1.9M
$-7.2M
Q2 24
$1.0M
$-12.8M
Q1 24
$4.1M
$-20.9M
Free Cash Flow
PDEX
PDEX
RCEL
RCEL
Q4 25
$3.5M
$-6.1M
Q3 25
$2.2M
$-6.2M
Q2 25
$-10.8M
Q1 25
$574.0K
$-10.5M
Q4 24
$-4.7M
$-9.7M
Q3 24
$1.5M
$-11.0M
Q2 24
$-15.4M
Q1 24
$4.0M
$-22.0M
FCF Margin
PDEX
PDEX
RCEL
RCEL
Q4 25
18.8%
-34.7%
Q3 25
11.9%
-36.1%
Q2 25
-58.4%
Q1 25
3.3%
-56.9%
Q4 24
-27.9%
-52.7%
Q3 24
9.8%
-56.1%
Q2 24
-101.6%
Q1 24
27.7%
-198.2%
Capex Intensity
PDEX
PDEX
RCEL
RCEL
Q4 25
0.4%
3.8%
Q3 25
0.5%
5.5%
Q2 25
2.8%
Q1 25
1.0%
1.2%
Q4 24
3.2%
8.8%
Q3 24
2.9%
19.2%
Q2 24
17.5%
Q1 24
0.8%
10.3%
Cash Conversion
PDEX
PDEX
RCEL
RCEL
Q4 25
1.63×
Q3 25
0.49×
Q2 25
-0.14×
Q1 25
0.23×
Q4 24
-2.03×
Q3 24
0.77×
Q2 24
0.66×
Q1 24
6.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons